Cost Estimation of Cardiovascular Disease Events in the US
暂无分享,去创建一个
David Thompson | David J. Cohen | Amy K. O’Sullivan | D. Cohen | Jaime Rubin | Joshua Nyambose | Andreas Kuznik | A. Kuznik | A. O’sullivan | J. Nyambose | J. Rubin | D. Thompson | D. Cohen | D. Cohen
[1] C. Pashos,et al. Long-Term Cost of Stroke Subtypes among Medicare Beneficiaries , 2006, Cerebrovascular Diseases.
[2] R. D'Agostino. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. , 2005, Statistics in medicine.
[3] F. Lampe,et al. The natural history of prevalent ischaemic heart disease in middle-aged men. , 2000, European heart journal.
[4] K. Anstrom,et al. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial. , 2008, American heart journal.
[5] M. Drummond,et al. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study , 2009, The European Journal of Health Economics.
[6] L. Goldman,et al. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. , 1987, American journal of public health.
[7] Dorte Gyrd-Hansen,et al. Costs of heart disease and risk behaviour: Implications for expenditure on prevention , 2008, Scandinavian journal of public health.
[8] J. Holmes,et al. Lifetime cost of stroke in the United States. , 1996, Stroke.
[9] S. Ramsey,et al. An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes , 2012, PharmacoEconomics.
[10] R. D'Agostino. Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .
[11] P. Sandercock,et al. Long‐term Survival After First‐Ever Stroke: The Oxfordshire Community Stroke Project , 1993, Stroke.
[12] Marcelo Coca-Perraillon. Local and Global Optimal Propensity Score Matching , 2007 .
[13] D. Huse,et al. Direct medical costs of coronary artery disease in the United States. , 1998, The American journal of cardiology.
[14] H. Birnbaum,et al. Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence. , 2003, Women's health issues : official publication of the Jacobs Institute of Women's Health.
[15] Ruth Davies,et al. The Development of a Simulation Model of the Treatment of Coronary Heart Disease , 2002, Health care management science.
[16] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.
[17] C N Smart,et al. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: a comparative analysis. , 1980, American journal of public health.
[18] Dean G. Smith,et al. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). , 2005, The American journal of cardiology.
[19] Melinda Beeuwkes Buntin,et al. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. , 2004, Journal of health economics.
[20] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[21] A Hofman,et al. The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.
[22] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[23] Bhash Naidoo,et al. The Development of a Simulation Model of Primary Prevention Strategies for Coronary Heart Disease , 2002, Health care management science.
[24] R B D'Agostino,et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. , 2000, American heart journal.
[25] Brown Wv. Framingham Heart Study. , 2011, Journal of clinical lipidology.
[26] M. Abrahamowicz,et al. The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity. , 1992, JAMA.
[27] J. Mullahy. Much Ado About Two: Reconsidering Retransformation and the Two-Part Model in Health Economics , 1998, Journal of health economics.